Article Text

Download PDFPDF

DAPSA versus cDAPSA: Do we need to use CRP?
  1. Rafaela Silva Guimarães Gonçalves,
  2. Lays Miranda de Almeida Martins,
  3. Henrique de Ataide Mariz,
  4. Andrea Tavares Dantas,
  5. Angela Luzia Branco Pinto Duarte
  1. Department of Rheumatology, Clinical Hospital of Federal University, Recife, Pernambuco, Brazil
  1. Correspondence to Dr Rafaela Silva Guimarães Gonçalves, Hospital das Clinicas de pernambuco, Recife 50670-901, Brazil; rafa_sgg{at}hotmail.com

Statistics from Altmetric.com

Introduction

In recent years, there has been a paradigm shift towards the development of disease activity indexes that correspond to the clinical measures and also the results reported by the patients, thus capturing the total burden of the disease.1

Disease Activity Index for Psoriatic Arthritis (DAPSA)2 is an index for measuring disease activity in psoriatic arthritis (PsA) that use C-reactive protein (CRP) as activity biomarker. Recently, van Mens et al1 shown that the use of clinical DAPSA (cDAPSA) was similar to DAPSA using CRP. Our objective is evaluating whether CRP influences the achievement of different DAPSA disease states, and therefore we compared DAPSA with and without CRP.

Methodology

Trained rheumatology collected clinical data from 124 eligible patients, including swollen and tender joint count (SJC 66 and TJC 68 joints).

DAPSA is calculated with the number of painful joints …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles